Treatment guidelines in polycythemia vera currently recommend maintaining hematocrit below 45%, with a higher threshold for ...

Polycythemia vera (PV ... High numbers for hemoglobin, hematocrit, or blood cell count can all be signs of PV. The CBC takes only a few minutes. Your doctor puts a thin needle into your arm ...

Topline data were announced from a phase 3 trial evaluating rusfertide in patients with polycythemia vera (PV ... in 293 PV patients with uncontrolled hematocrit who are phelobotomy-dependent ...

Many people with polycythemia vera (PV) live a normal life with this rare blood cancer under control. The goal is to avoid complications like blood clots, which may happen because PV thickens your ...

A panelist discusses how they prioritize specific clinical and laboratory parameters when assessing response to first-line ...

The reduction of hematocrit below 45% is a primary treatment ... placebo-controlled trial evaluating rusfertide in 293 patients with polycythemia vera over a 156-week period.

Many patients with polycythemia vera, the news release noted ... undergo phlebotomy — described as a process of removing blood to manage elevated levels of hematocrit, or the percentage of red blood ...

Polycythemia vera is a type of blood cancer ... The other three pre-specified key secondary endpoints, namely hematocrit control and patient-reported outcomes using PROMIS Fatigue SF-8a3 and ...

maintained durable hematocrit control, and reduced the need for therapeutic phlebotomy in polycythemia vera patients. Protagonist Therapeutics expects to finalize the study report and submit it to ...

The primary endpoint of the study was met, with a significantly higher proportion of clinical responders 1 among rusfertide-treated patients with PV (77%) compared to those who received placebo ...